Exelixis (NASDAQ: EXEL) — Perfil da empresa, notícias e dados financeiros
Exelixis is a biotechnology company focused on developing innovative cancer therapies to improve patient outcomes.
Exelixis
Exelixis is a biotechnology company focused on the discovery, development, and commercialization of new medicines for cancer. Founded in 1994, the company focuses on advancing therapeutics for complex oncological conditions. Its portfolio features commercialized small molecule targeted therapies, as well as an expanding pipeline of biotherapeutics and next-generation candidates, including bispecific antibodies and antibody-drug conjugates. Exelixis operates across internal discovery research, clinical development, and commercial operations to treat various tumor types, collaborating with pharmaceutical and biotechnology partners worldwide to expand the reach and evaluation of its investigational and approved therapies.
Resumo
Operações
Produtos e/ou serviços de Exelixis
- Commercial Small Molecule Therapies: Targeted oral small molecule tyrosine kinase inhibitors developed for the treatment of advanced renal cell carcinoma, previously treated hepatocellular carcinoma, and differentiated thyroid cancer across major global medical markets.
- Metastatic Medullary Thyroid Cancer Treatments: Specialized capsule formulations targeting receptor tyrosine kinases, specifically indicated for the treatment of progressive, metastatic medullary thyroid cancer, providing targeted oral therapeutic options in oncology centers worldwide.
- Next-Generation Kinase Inhibitors: Advanced investigational oral multikinase inhibitors entering pivotal Phase 3 clinical evaluation for metastatic colorectal cancer, non-clear cell renal cell carcinoma, and additional advanced solid tumor indications.
- Antibody-Drug Conjugates and Biotherapeutics: Targeted biotherapeutic candidates including antibody-drug conjugates and bispecific antibodies engineered to selectively deliver therapeutic payloads or enhance localized immune responses against specific solid tumor targets.
- Internal Small Molecule Discovery Engine: Comprehensive early-stage discovery programs leveraging target validation, medicinal chemistry, structural biology, and translational research to identify novel small molecule drug candidates for complex oncology targets.
- Strategic Oncology R&D Collaborations: Collaborative development, co-funding, and licensing agreements with global pharmaceutical and biotechnology partners to evaluate combination therapy regimens, expand clinical indications, and accelerate global commercialization.
equipe executiva do Exelixis
- Stelios PapadopoulosCo-Founder & Independent Chair of the Board
- Michael M. MorrisseyCEO, President & Director
- Christopher J. SennerExecutive VP & CFO
- Brenda J. HeftiSenior VP & General Counsel
- Dana T. AftabExecutive Vice President of Research & Development
- Patrick Joseph HaleyExecutive Vice President of Commercial
- William BergSenior Vice President of Medical Affairs
- Stefan KraussVP & Head of Business Development
- Andrew Ross PetersSenior Vice President of Strategy
- Deborah BurkeSenior VP of Finance & Controller
Principais indicadores financeiros
Resultados divulgados pela Exelixis, em USD.
- Cap. de mercado
- 16,2 bi
- Receita (TTM)
- 2,4 bi
- P/L
- 20.6
- LPA (diluído, TTM)
- 3.2
- Dividend yield
- —
- Margem de lucro
- 35.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 2,3 bi | 872,2 mi | 782,6 mi | |
| 2,2 bi | 604,6 mi | 521,3 mi | |
| 1,8 bi | 170,9 mi | 207,8 mi | |
| 1,6 bi | 201,5 mi | 182,3 mi |